General aspects of anti-angiogenesis and cancer therapy

被引：40

作者：

Zogakis, TG ^{[1
]}

Libutti, SK ^{[1
]}

机构：

[1] NCI, Surg Branch, Bethesda, MD 20892 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2001年 / 1卷 / 02期

关键词：

angiogenesis; cancer therapy; carboxyamido-triazole; endostatin; IL-12; matrix metalloproteinases; suramin; thalidomide; VEGF;

D O I：

10.1517/14712598.1.2.253

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated.

引用

页码：253 / 275

页数：23

共 197 条

[1]

Alessandro R, 1996, IN VIVO, V10, P153

[2]

Angelov L, 1999, CANCER RES, V59, P5536

[3]

[Anonymous], P AM SOC CLIN ONCOLO

[4]

Atkins MB, 1997, CLIN CANCER RES, V3, P409

[5] Phase II evaluation of thalidomide in patients with metastatic breast cancer [J].

Baidas, SM ;

Winer, EP ;

Fleming, GF ;

Harris, L ;

Pluda, JM ;

Crawford, JG ;

Yamauchi, H ;

Isaacs, C ;

Hanfelt, J ;

Tefft, M ;

Flockhart, D ;

Johnson, MD ;

Hawkins, MJ ;

Lippman, ME ;

Hayes, DF .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2710-2717

[6]

Bauer KS, 1999, CLIN CANCER RES, V5, P2324

[7] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].

Bauer, KS ;

Dixon, SC ;

Figg, WD .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834

[8] Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice [J].

Beecken, WDC ;

Fernandez, A ;

Panigrahy, D ;

Achilles, EG ;

Kisker, O ;

Flynn, E ;

Joussen, AM ;

Folkman, J ;

Shing, Y .

UROLOGY, 2000, 56 (03) :521-526

[9] MMP inhibitors: experimental and clinical studies [J].

Belotti, D ;

Paganoni, P ;

Giavazzi, R .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (04) :232-238

[10] Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor [J].

Berlin, J ;

Tutsch, KD ;

Hutson, P ;

Cleary, J ;

Rago, RP ;

Arzoomanian, RZ ;

Alberti, D ;

Feierabend, C ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :781-789

← 1 2 3 4 5 6 7 8 9 10 →